Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia

Journal of Clinical Oncology

Volumn 31, Issue 34, 2013, Pages 4283-4289

  Aarts, Maureen J ^a   Grutters, Janneke P ^a   Peters, Frank P ^b   Mandigers, Caroline M ^c   Dercksen, M Wouter ^d   Stouthard, Jacqueline M ^e   Nortier, Hans J ^f   Van Laarhoven, Hanneke W ^g   Van Warmerdam, Laurence J ^h   Van De Wouw, Agnes J ⁱ   Jacobs, Esther M ^j   Mattijssen, Vera ^k   Van Der Rijt, Carin C ^l   Smilde, Tineke J ^m   Van Der Velden, Annette W ⁿ   Temizkan, Mehmet ^o   Batman, Erdogan ^p   Muller, Erik W ^q   Van Gastel, Saskia M ^r   Joore, Manuela A ^a   Borm, George F ^g   Tjan Heijnen, Vivianne C ^a   more..

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Sittard Geleen Heerlen   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d MÁXIMA MEDICAL CENTER   (Netherlands)

^e Maasstad Hospital Rotterdam   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h CATHARINA HOSPITAL   (Netherlands)

ⁱ VIECURI MEDICAL CENTER   (Netherlands)

^j ELKERLIEK HOSPITAL   (Netherlands)

^k RIJNSTATE HOSPITAL   (Netherlands)

^l ERASMUS MEDICAL CENTER   (Netherlands)

^m JEROEN BOSCH HOSPITAL   (Netherlands)

ⁿ MARTINI HOSPITAL   (Netherlands)

^o ST JANSDAL HOSPITAL   (Netherlands)

^p Diaconessenhuis Leiden   (Netherlands)

^q SLINGELAND HOSPITAL   (Netherlands)

^r Integraal Kankercentrum Oost   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; PEGFILGRASTIM; RECOMBINANT PROTEIN;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BLOOD TRANSFUSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOPROPHYLAXIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FEBRILE NEUTROPENIA; FEMALE; GENERAL PRACTITIONER; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX RADIOGRAPHY; ULTRASOUND; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; DRUG COST; ECONOMICS; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; MODELS, ECONOMIC; NETHERLANDS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892936067     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.48.3644     Document Type: Article

References (24)

1. Kuderer NM, Dale DC, Crawford J, et al: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106: 2258-2266, 2006 (Pubitemid 43673249)
2. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with smallcell lung cancer. N Engl J Med 325:164-170, 1991
3. Ozer H, Armitage JO, Bennett CL, et al: 2000 update of recommendations for the use of haematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines - American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18:3558- 3585, 2000
4. Aapro MS, Bohlius J, Cameron DA, et al: 2010 update of EORTC guidelines for the use of granulocyte colony-stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8-32, 2011
5. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidencebased clinical practice guideline. J Clin Oncol 24:3187-3205, 2006 (Pubitemid 46638957)
6. National Comprehensive Cancer Network: Myeloid growth factors: Practice guidelines in the oncology, version 1.2010. www.nccn.org/professionals/ physician-gls/f-guidelines.asp#supportive
7. Aarts MJ, Peters FP, Mandigers CM, et al: Primary G-CSF prophylaxis during the first two cycles only or throughout all chemotherapy cycles in breast cancer patients at risk of febrile neutropenia). J Clin Oncol 10.1200/JCO.2012.44.6229
8. Martín M, Lluch A, Seguí MA, et al: Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorourail, doxorubicin and cyclophosphamide (FAC): Impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 17:1205-1212, 2006 (Pubitemid 44288210)
9. Nabholtz JM, Cantin J, Chang J, et al: Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: Results of the BCIRG 004 trial. Clinical Breast Cancer 3:268-275, 2002 (Pubitemid 35423147)
10. Tjan-Heijnen VC, Postmus PE, Ardizzoni A, et al: Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study. Ann Oncol 12:1359-1368, 2001 (Pubitemid 33100239)
11. Hakkart-van Roijen L, Tan SS, Bouwmans CAM: Manual for cost research. Dutch Health Care Insurance Board, 2010. (in Dutch). www.cvz.nl/binaries/ content/ documents/cvzinternet/nl/documenten/losse-publicaties/ handleiding-kostenonderzoek-2010.pdf
12. College voor Zorgverzekeringen: Pharmacotherapeutic Compass (in Dutch). www.fk.cvz.nl
13. Central Bureau for Statistics: Statline (in Dutch). Available from http://statline.cbs.nl
14. Briggs AH, Wonderling DE, Mooney CZ, et al: Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation. Health Econ 6:327-340, 1997 (Pubitemid 27384638)
15. van Hout BA, Al MJ, Gordon GS, et al: Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 3:309-319, 1994
16. Klastersky J, Paesmans M, Rubenstein EB, et al: The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038-3051, 2000 (Pubitemid 30644129)
17. Vriens BE, Lobbezoo DJ, de Hoon JP, et al: If there is no overall survival benefit in metastatic breast cancer: Does it imply lack of efficacy? Taxanes as an example. Cancer Treat Rev 39:189-198, 2013
18. Martín-Jiménez M, Rodríguez-Lescure A, Ruiz-Borrego M, et al: Cost-effectiveness analysis of docetaxel (Taxotere) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer. Clin Transl Oncol 11:41-47, 2009
19. Ward S, Simpson E, Davis S, et al: Taxanes for the adjuvant treatment of early breast cancer: Systematic review and economic evaluation. Health Technol Assess 11:1-144, 2007
20. Timmer-Bonte JN, Adang EM, Smit HJ, et al: Cost-effectiveness of adding granulocyte colonystimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol 24: 2991-2997, 2006 (Pubitemid 46638931)
21. Geurts SM, van Dijck JAAM, de Vegt F, et al: Huge decrease in risk of breast cancer relapse in the Netherlands over the last 3 decades. Eur J Cancer 48:S82-S83, 2012 (suppl 1)
22. Schelenz S, Giles D, Abdallah S: Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre. Ann Oncol 23:1889-1893, 2012
23. Lingaratnam S, Thursky KA, Slavin MA, et al: The disease and economic burden of neutropenic fever in adult patients in Australian cancer treatment centres 2008: Analysis of the Victorian Admitted Episodes Dataset. Intern Med J 41:121- 129, 2011
24. Essers BA, Seferina SC, Tjan-Heijnen VC, et al: Transferability of model-based economic evaluations: The case of trastuzumab for the adjuvant treatment of HER2-positive early breast cancer in the Netherlands. Value Health 13:375-380, 2010